Min menu


Oxford vaccine against the Oxford coronavirus: 70% effective

Oxford vaccine against the Oxford coronavirus: 70% effective

Oxford vaccine against the Oxford coronavirus: 70% effective

The coronavirus vaccine developed by the University of Oxford tries to 70% of people to develop symptoms of the coronavirus, as shown in a large-scale trial.

It's both a triumph and a disappointment after the vaccines from Pfizer and Moderna showed 95% protection.

However, the Oxford vaccine is much cheaper and easier to store and transport around the world than the other two.

It therefore continues to play an important role in the fight against the pandemic, if approved by regulatory authorities.

There is also intriguing evidence that dose enhancement could increase protection by up to 90%.

Oxford researchers have successfully completed the process, which normally lasts ten years, and which consists of developing a vaccine in ten months.

"Today's announcement brings us closer to when we can use vaccines to end the devastation caused by [the virus]," says its designer Professor Sarah Gilbert.

The British government has pre-ordered 100 million doses of the Oxford vaccine, enough to immunize 50 million people.

What did the test show?

Oxford vaccine against the Oxford coronavirus: 70% effective

Over 20,000 volunteers have been used, half in the UK, the rest in Brazil.

There have been 30 cases of Covid in people who received two doses of the vaccine and 101 cases in people who received a dummy injection.

'The researchers said the protection rate was 70%'.

When volunteers received two "high" doses, the protection was 62%, but increased to 90% when people received a "low" dose followed by a high dose. It is not clear why there is a difference.

"We are very satisfied with these results," Professor Andrew Pollard, the trial's lead investigator, told the BBC.

He said the data on 90% efficacy was "intriguing" and that meant "we would have a lot more doses to give out."

When will we get it?

Oxford vaccine against the Oxford coronavirus: 70% effective

In the UK there are four million doses ready for use, and an additional 96 million doses need to be distributed.

But nothing can happen until the vaccine has been approved by the regulatory authorities who assess the vaccine's safety and efficacy, and the vaccine is manufactured to high standards. 'This process will take place in the coming weeks'.

However, the UK is set to launch an unprecedented mass vaccination campaign that overshadows annual flu vaccination programs or childhood vaccination programs.

Residents and nursing home staff will be the first to receive, followed by health workers and those over 85. It is planned to then descend into the different age groups.

How does it work?

The vaccine is a genetically modified cold virus that once infected chimpanzees.

It has been modified to prevent it from causing infection in humans and to carry blueprints for part of the coronavirus, known as the spike protein.

Once these blueprints are inside the body, they begin to produce the coronavirus spike protein, which the immune system recognizes as a threat and tries to crush it.

When the immune system actually comes into contact with the virus, it now knows what to do.

Are the results disappointing?

Oxford vaccine against the Oxford coronavirus: 70% effective

After Pfizer and Moderna both produced vaccines that offered 95% protection against Covid-19, a relatively disappointing 70% figure.

However, anything over 50% would have been considered a triumph just a month ago.

This vaccine can also be stored at refrigerator temperature, which means it can be distributed to four rooms around the world, unlike the Pfizer / BioNTech and Moderna vaccines, which must be stored at much cooler temperatures.

I have ambitions and goals in my life, and I am now trying to achieve them calmly, as the name also came on my channel and website.